Beacon Therapeutics

Today, we announced the appointment of Lance Baldo, MD as CEO, effective August 12, 2024, and Thomas Biancardi as CFO, effective August 1, 2024. Current CEO, David Fellows was named non-Executive Chairman of the Board, effective January 2025. Lance and Tom bring a wealth of experience in biopharmaceuticals and ophthalmology and share our passion to develop potentially transformative ocular gene therapies for patients. We are thankful to Dave for his leadership and excited to welcome Lance and Tom to the Beacon team in August! To learn more about these executive appointments, please click the link to the press release below. https://lnkd.in/e823cD5P

Thanks to Rajiv Anand, MD, FRCS, FASRS for presenting an encore of the 12-month interim safety and efficacy results of the Phase 2 SKYLINE trial in patients with X-linked retinitis pigmentosa (XLRP) at the ASRS – American Society of Retina Specialists 2024 Annual Scientific Meeting in Stockholm, Sweden. We look forward to sharing 24-month data from the Phase 2 SKYLINE trial later this year. To learn more about the work we are doing at Beacon to bring transformative ocular gene therapies to patients, please visit https://www.beacontx.com/ #ASRS2024 #XLRP

In case you missed the news last week, there was a lot of great coverage on the successful closing of our $170 million Series B, a significant milestone on our journey to bring potentially transformative gene therapies to patients with blinding retinal diseases. For more information, please visit https://www.beacontx.com/

We are thrilled to announce the successful closing of our $170 million Series B, led by Forbion with contributions from existing investors Syncona Limited Oxford Science Enterprises and University of Oxford, as well as initial investments from TCGX and Advent Life Sciences. This represents a significant milestone in our journey to bring potentially transformative treatments to patients with blinding retinal diseases. The funds will be used to support the continued clinical development of AGTC-501 for X-Linked Retinitis Pigmentosa (XLRP) and our Dry Age-related Macular Degeneration (dAMD) program. To read more about our Series B funding and pipeline momentum, click the link to the press release below. https://lnkd.in/eZ9mrd6K #genetherapy #ophthalmology #biotech #seriesB

Beacon Therapeutics is pleased to announce that the first patient has been treated in our Phase 2/3 VISTA clinical trial for our lead asset, AGTC-501. This is an important clinical milestone for AGTC-501 and another promising step toward a potential treatment for patients with X-Linked Retinitis Pigmentosa (XLRP), a blinding orphan disease for which there is no available treatment. VISTA is a randomized, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 doses of AGTC-501 for the treatment of XLRP compared to an untreated control group. To learn more about our ongoing VISTA trial, click the link to the press release below. https://lnkd.in/ePRK4FJW

Happy to be supporting this great event! #RIWC24

Beacon will be attending #BIO2024! Thank you to our team members representing Beacon - Amy Christenson Parker Davenport and Amy Adelman House. You can also see Amy House on the "Changing Clinical Trial Designs in the IRA Environment and Impacts on Stakeholders in Rare and Ultra-Rare Disease" panel on June 5. #genetherapy #raredisease #ophthalmology

Thank you to HealthLeaders for highlighting our CEO David Fellows and the work we are doing at Beacon on our mission to save the restore the vision of patients with blinding retinal diseases.

We were excited to see Prof Robert MacLaren included in The Ophthalmologist Power List 2024. Robert is a scientific co-founder and board member at Beacon Therapeutics. Congratulations to Robert on this well-deserved honor! https://lnkd.in/eqRjC89H #ophthalmology

Beacon Therapeutics is attending the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Baltimore! Our team would be happy to discuss our mission to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. Thank you to Abraham Scaria Amy Adelman House Brendan M Zangari Bruno Doreste and Khalid Arhzaouy for representing Beacon at ASGCT 2024. #ASGCT2024 #genetherapy